These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23865387)

  • 1. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Mori Y; Okuda Y; Hiramatsu K;
    Clin Exp Hypertens; 2014; 36(4):236-43. PubMed ID: 23865387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
    Chapman RH; Petrilla AA; Berman L; Benner JS; Tang SS
    Am J Cardiovasc Drugs; 2009; 9(5):299-308. PubMed ID: 19791839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.
    Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Sato Y; Okuda Y; Shirayama M
    J Atheroscler Thromb; 2015; 22(1):62-75. PubMed ID: 25168847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study.
    Yoshida H; Shimizu M; Ikewaki K; Taniguchi I; Tada N; Yoshimura M; Rosano G; Dahlöf B; Mochizuki S;
    J Hypertens; 2010 Jun; 28(6):1150-7. PubMed ID: 20467269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K; Kondo T; Muramatsu T; Matsushita K; Nagahiro T; Maeda K; Shintani S; Murohara T
    Am J Cardiol; 2013 Dec; 112(11):1750-6. PubMed ID: 24035165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
    Shiraishi J; Sawada T; Koide M; Yamada H; Matsubara H;
    Am J Cardiol; 2012 May; 109(9):1308-14. PubMed ID: 22325086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors.
    Teramukai S; Okuda Y; Miyazaki S; Kawamori R; Shirayama M; Teramoto T
    Hypertens Res; 2016 Feb; 39(2):113-8. PubMed ID: 26606874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of workload at the heart rate of 100 beats/min in predicting cardiovascular mortality in men aged 42, 48, 54, or 60 years at baseline.
    Savonen KP; Lakka TA; Laukkanen JA; Rauramaa TH; Salonen JT; Rauramaa R
    Am J Cardiol; 2007 Aug; 100(4):563-8. PubMed ID: 17697806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events.
    Zhang Y; Pletcher MJ; Vittinghoff E; Clemons AM; Jacobs DR; Allen NB; Alonso A; Bellows BK; Oelsner EC; Zeki Al Hazzouri A; Kazi DS; de Ferranti SD; Moran AE
    JAMA Cardiol; 2021 Dec; 6(12):1406-1413. PubMed ID: 34550307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Perceived stress and cardiovascular disease mortality. The Ohsaki Cohort Study].
    Kowata E; Hozawa A; Kakizaki M; Tomata Y; Nagai M; Sugawara Y; Kuriyama S; Tsuji I
    Nihon Koshu Eisei Zasshi; 2012 Feb; 59(2):82-91. PubMed ID: 22642183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    Tonkin A; Hunt D; Voysey M; Kesäniemi A; Hamer A; Waites J; Mahar L; Mann S; Glasziou P; Forder P; Simes J; Keech AC;
    Am Heart J; 2012 Mar; 163(3):508-14. PubMed ID: 22424024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
    Suzuki H; Kanno Y;
    Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Anderson RE; Pfeffer MA; Thune JJ; McMurray JJ; Califf RM; Velazquez E; White HD; Rouleau JL; Skali H; Maggioni A; Solomon SD
    Am Heart J; 2008 Apr; 155(4):706-11. PubMed ID: 18371480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study.
    Harriss LR; English DR; Hopper JL; Powles J; Simpson JA; O'Dea K; Giles GG; Tonkin AM
    Addiction; 2007 Oct; 102(10):1574-85. PubMed ID: 17854334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.